Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
30
NVO Quote, Financials, Valuation and Earnings
Last price:
$50.87
Seasonality move
:
3.8%
Day range:
$50.55 - $51.26
52-week range:
$43.08 - $93.80
Dividend yield:
3.4%
P/E ratio:
14.82x
P/S ratio:
4.85x
P/B ratio:
11.15x
Volume:
10.8M
Avg. volume:
18.5M
1-year change:
-40.85%
Market cap:
$226.1B
Revenue:
$42.1B
EPS (TTM):
$3.43
Analysts' Opinion
-
Consensus RatingNovo Nordisk A/S has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 4 Hold ratings, and 2 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $53.33, Novo Nordisk A/S has an estimated upside of 5.18% from its current price of $50.88.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $42.00 representing 100% downside risk from its current price of $50.88.
Fair Value
-
According to the consensus of 11 analysts, Novo Nordisk A/S has 5.18% upside to fair value with a price target of $53.33 per share.
NVO vs. S&P 500
-
Over the past 5 trading days, Novo Nordisk A/S has underperformed the S&P 500 by -0.2% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Novo Nordisk A/S does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Novo Nordisk A/S has grown year-over-year revenues for 21 quarters straight. In the most recent quarter Novo Nordisk A/S reported revenues of $11.7B.
Earnings Growth
-
Novo Nordisk A/S earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Novo Nordisk A/S reported earnings per share of $0.70.
Enterprise value:
236.9B
EV / Invested capital:
--
Price / LTM sales:
4.85x
EV / EBIT:
11.96x
EV / Revenue:
5.07x
PEG ratio (5yr expected):
1.31x
EV / Free cash flow:
25.62x
Price / Operating cash flow:
24.52x
Enterprise value / EBITDA:
10.28x
Gross Profit (TTM):
$38.3B
Return On Assets:
21.76%
Net Income Margin (TTM):
32.76%
Return On Equity:
68.76%
Return On Invested Capital:
41.85%
Operating Margin:
31.74%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $30.8B | $39.3B | $46.7B | $10.5B | $11.7B | |
| Gross Profit | $25.9B | $33.3B | $38.3B | $8.8B | $8.9B | |
| Operating Income | $13.3B | $17.3B | $19.8B | $5B | $3.7B | |
| EBITDA | $14.5B | $19.7B | $23B | $5.3B | $4.9B | |
| Diluted EPS | $2.41 | $3.08 | $3.43 | $0.90 | $0.70 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $14.2B | $15.7B | $20.2B | $29.2B | $28.6B | |
| Total Assets | $27.1B | $32B | $42.6B | $59.5B | $80.6B | |
| Current Liabilities | $13.8B | $17.2B | $24.5B | $31.2B | $36.9B | |
| Total Liabilities | $16.8B | $21.9B | $29.4B | $41.5B | $53.9B | |
| Total Equity | $10.3B | $10.1B | $13.2B | $18B | $26.7B | |
| Total Debt | $1.9B | $3.2B | $2.8B | $7.7B | $14B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $15.3B | $17.2B | $18.7B | $6.4B | $7.3B | |
| Cash From Investing | -$6.2B | -$7.6B | -$18.8B | -$3.1B | -$2.4B | |
| Cash From Financing | -$8.7B | -$5.6B | -$3.4B | -$2.7B | -$2.8B | |
| Free Cash Flow | $11.1B | $9.8B | $9.2B | $4.6B | $4.8B | |
NVO
Sector
Market Cap
$226.1B
$27.6M
Price % of 52-Week High
54.24%
50.06%
Dividend Yield
3.4%
0%
Shareholder Yield
5.06%
-1.55%
1-Year Price Total Return
-40.85%
-18.12%
Beta (5-Year)
0.665
0.516
Dividend yield:
3.4%
Annualized payout:
$1.45
Payout ratio:
--
Growth streak:
5 years
Technicals
8-day SMA
Buy
Level
$50.79
200-day SMA
Sell
Level
$59.91
Bollinger Bands (100)
Sell
Level
48.5 - 57
Chaikin Money Flow
Buy
Level
1.8B
20-day SMA
Buy
Level
$49.36
Relative Strength Index (RSI14)
Buy
Level
54.93
ADX Line
Buy
Level
16.04
Williams %R
Neutral
Level
-44.9714
50-day SMA
Buy
Level
$49.28
MACD (12, 26)
Buy
Level
0.61
25-day Aroon Oscillator
Buy
Level
80
On Balance Volume
Neutral
Level
1.7B
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (7.0926)
Buy
CA Score
(Annual)
Level (0.6478)
Buy
Beneish M-Score
(Annual)
Level (-2.5103)
Sell
Momentum Score
Level (2)
Buy
Ohlson Score
Level (-1.1185)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.
Stock Forecast FAQ
In the current month, NVO has received 5 Buy ratings 4 Hold ratings, and 2 Sell ratings. The NVO average analyst price target in the past 3 months is $53.33.
-
Where Will Novo Nordisk A/S Stock Be In 1 Year?
According to analysts, the consensus estimate is that Novo Nordisk A/S share price will rise to $53.33 per share over the next 12 months.
-
What Do Analysts Say About Novo Nordisk A/S?
Analysts are divided on their view about Novo Nordisk A/S share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Novo Nordisk A/S is a Sell and believe this share price will drop from its current level to $42.00.
-
What Is Novo Nordisk A/S's Price Target?
The price target for Novo Nordisk A/S over the next 1-year time period is forecast to be $53.33 according to 11 Wall Street analysts, 5 of them rate the stock a Buy, 2 rate the stock a Sell, and 4 analysts rate the stock a Hold.
-
Is NVO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Novo Nordisk A/S is a Buy. 5 of 11 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of NVO?
You can purchase shares of Novo Nordisk A/S via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Novo Nordisk A/S shares.
-
What Is The Novo Nordisk A/S Share Price Today?
Novo Nordisk A/S was last trading at $50.87 per share. This represents the most recent stock quote for Novo Nordisk A/S. Yesterday, Novo Nordisk A/S closed at $50.88 per share.
-
How To Buy Novo Nordisk A/S Stock Online?
In order to purchase Novo Nordisk A/S stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get NVO Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
NVO
Sector
P/E ratio
14.82x
23.89x
PEG ratio
1.31x
-0.01x
P/B ratio
11.15x
1.81x
Price / LTM sales
4.85x
1.58x
Growth Metrics
NVO
Sector
Revenue growth
11.8%
4.6%
Earnings growth
-21.84%
10.88%
Revenue (5-year growth)
18.15%
6.46%
Earnings forecast
$0.92
-$0.18
Profitability
NVO
Sector
Profitability FY 2024
$35.3B
$3.6M
Return on invested capital
41.85%
-31.84%
Return on assets
21.76%
-27.96%
Return on equity
68.76%
-37.63%
Earnings Date
Last Earnings Date
Nov
5
Next Earnings Date
Feb
4
Estimated Next Earnings Date
Feb
4
Balance Sheet
NVO
Sector
Total cash
$5.1B
$26.3M
Short term investments
$1.5B
$25.7M
Total assets
$64.7B
$78M
Long term debt
$14B
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
30
CORT alert for Jan 1
Corcept Therapeutics, Inc. [CORT] is down 50.44% over the past day.
Buy
75
AXSM alert for Jan 1
Axsome Therapeutics, Inc. [AXSM] is up 22.82% over the past day.
Buy
81
ZIJMY alert for Jan 1
Zijin Mining Group Co., Ltd. [ZIJMY] is up 1.86% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
